Trial Profile
Functional Respiratory Imaging (FRI) to Assess the Short-term Effect of the Product ORKAMBI (Lumacaftor/ Ivacaftor) on Lung Function in ORKAMBInaive Patients With Cystic Fibrosis Homozygous for Phe508del
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2020
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 07 Apr 2020 Status changed from completed to discontinued.
- 04 Apr 2020 Status changed from recruiting to completed.